TLDR:
– Diagonal Therapeutics has launched with $128 million in financing
– The company is focused on developing new agonist antibodies for severe diseases
Diagonal Therapeutics, a biotechnology company based in Cambridge, MA, has raised $128 million in funding from investors such as BVF Partners and Atlas Venture. The company plans to use this funding to further advance its proprietary platform and pipeline of novel therapeutics, with a focus on treating hereditary hemorrhagic telangiectasia (HHT), a severe bleeding disorder.
The company’s platform combines computational and experimental techniques to discover agonist antibody candidates, with a goal of addressing the underlying causes of diseases. Diagonal has already identified antibody candidates for complex targets related to HHT and pulmonary arterial hypertension (PAH), offering new treatment options for patients.
